Mississippi HB314 authorizes the State Department of Health to select a consortium for an ibogaine drug development clinical trial to secure FDA.
Mississippi HB314, known as the Ibogaine Drug Development Clinical Trial Act, authorizes the State Department of Health to select a consortium to conduct a clinical trial for ibogaine, aiming to secure FDA approval for treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The selected consortium must include a drug developer, an institution of higher learning, and a hospital. The consortium must submit a proposal detailing the trial strategy, budget, timeline, and revenue allocation.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.